Micro-, Small-Cap Firms Dominate Market Rally

3. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Shares of Tonix Pharmaceuticals jumped for a third day on Thursday, adding 33.49 percent to its valuation to close at $14.63 apiece as investors gobbled up shares in the company ahead of an investor summit next week.

TNXP, a fully integrated biopharmaceutical firm, said that it would present at the 2025 Virtual Investor Summit on Tuesday, March 11, where investors would look out for cues and updates on its TNX-102 SL, a priority product candidate that aims to manage fibromyalgia.

TNXP said it expects to receive the decision of the Food and Drug Administration on the marketing authorization of the product on August 15, 2025.

Apart from TNX-102 SL, its portfolio also includes TNX-1300, a biologic in Phase 2 development designed to treat cocaine intoxication.